Allogeneic transplantation for Hodgkin lymphoma

British Journal of Haematology
K S PeggsAnna Sureda

Abstract

The majority of patients with Hodgkin lymphoma (HL) can now expect to be cured with conventional chemo- and/or radio-therapy. However, a subgroup still exists that have poor outcomes, even following dose escalation and autologous stem cell transplantation. Furthermore, patients relapsing after autografting have limited therapeutic options available. Whilst the application of allogeneic transplantation strategies has historically been limited by prohibitive transplant-related mortality, the exploration of reduced intensity approaches has demonstrated the feasibility of delivering allogeneic immunotherapies with more acceptable mortality rates. Although its role remains controversial, we are beginning to re-evaluate the use of allogeneic transplantation in the management of patients with HL and to address a number of critical questions. These include whether a clinically relevant graft-versus-tumour response occurs in HL, and whether subgroups of patients who might benefit from allogeneic approaches can be identified in order to inform development of rational clinical studies. This review focuses on evaluating recent experience with reduced intensity allogeneic approaches in HL in order to inform opinion on its current role and t...Continue Reading

References

Jun 1, 1991·Proceedings of the National Academy of Sciences of the United States of America·H HerbstH Stein
Feb 11, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D L LongoV T Devita
Jan 1, 1987·Virchows Archiv. A, Pathological Anatomy and Histopathology·T LöningJ Becker
Dec 1, 1970·Annals of Internal Medicine·V T DevitaP P Carbone
Sep 8, 1994·The New England Journal of Medicine·Helen E HeslopCliona M Rooney
Dec 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J E AndersonJ E Sanders
Feb 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J L GajewskiM M Horowitz
Apr 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·N MilpiedA H Goldstone
Oct 23, 1997·Hematology/oncology Clinics of North America·E J Rodriguez-Monge, F Cabanillas
Mar 18, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H M LazarusM M Horowitz
Jul 23, 1999·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J AparicioM Pastor
Jul 25, 2000·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·L J Johnston, Sandra J Horning
Mar 7, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Anna SuredaGrupo Español de Linformas/Transplante Autólogo de Médula Osea Spanish Cooperative Group
Dec 4, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G AkpekR J Jones
Apr 2, 2002·Best Practice & Research. Clinical Haematology·K S Peggs, S Mackinnon
Dec 22, 2004·The Journal of Experimental Medicine·Catherine M BollardHelen E Heslop
Jan 31, 2006·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Ivan AlvarezJorge Sierra
Aug 10, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Frédéric BaronBrenda M Sandmaier
Nov 23, 2006·Cancer Investigation·Volker Diehl, K Behringer
Jan 24, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce D ChesonInternational Harmonization Project on Lymphoma
Jan 24, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Malik E JuweidImaging Subcommittee of International Harmonization Project in Lymphoma
Aug 19, 2007·Leukemia & Lymphoma·Lieselot BrepoelsGregor Verhoef
Aug 22, 2007·Blood·Pamela SeamBruce D Cheson
Feb 19, 2008·British Journal of Haematology·Pauline Brice
Mar 18, 2008·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Philippe ArmandEdwin P Alyea

Citations

Mar 6, 2012·The Oncologist·Radhakrishnan Ramchandren
Aug 29, 2014·Stem Cells International·Gregory E TullisMark D Kirk
Feb 6, 2014·British Journal of Haematology·Girish VenkataramanVolker Diehl
Jul 2, 2016·Clinical Lymphoma, Myeloma & Leukemia·Amir K Issa, Jason R Westin

Related Concepts

Hodgkin Lymphoma, Lymphocyte Depletion
Relapse
Hemopoietic Stem Cell Transplant
Transplantation Conditioning
Graft Vs Tumor Effect
Clinical Research
Graft-vs-Host Disease
Hodgkin Disease
Immunotherapy
Transplantation, Homologous

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.